易伟
职务:
广州医科大学药学院副院长
职称:
教授
研究方向:
慢性气道疾病
研究工作:
围绕“靶向设计与合成—新药筛选与发现—作用靶点结构解析—分子机制探究”这一当代药物研发流程进行相互渗透、有机融合,同时结合计算机辅助药物设计、药物化学、有机合成化学、分子药理学、结构生物学等各个学科的交叉优势,而聚焦开展“基于核受体蛋白(GR与PPARγ)的高效安全的靶向创新药物设计、合成与发现”研究工作。研究领域主要聚焦:
1、基于关键靶蛋白的原创药物设计、合成与发现;
2、有机药物化学生物学。
科研项目:
1、国家自然科学基金面上项目,82273795,新型靶向GR配体结合域(LBD)-螺旋-1的选择性调控剂的 设计与发现及其作用机制研究, 2023-01至2026-12,52万元,主持
2、广州市"岭南英杰"工程国家级后备人才项目, Q847003,基于结构的创新药物设计与发现,2019-05至2023-05,125万元,主持
3、广东省高等教育“创新强校工程”创新团队项目,B195001282,基于靶蛋白结构的新药设计与发现创新团队,2019-01至2021-12,50万元,主持
4、国家自然科学基金面上项目,21877020,基于结构的新型PPARγ选择性调控剂靶向吲哚衍生物的设计、合成及其抗II型糖尿病作用机制探究, 2019-01至2021-12,65万元,主持
5、广东省自然科学杰出青年基金,2017A030306031,基于结构的新型PPARγ选择性调控剂作为抗II型糖尿病候选药物发现及其调控机制研究,2017-05至2021-05,100万,主持
代表性学术论文:
1、Nanozyme engineering in structurally explicit framework: Design mechanisms and biosensing applications Coord. Chem. Rev. 2024, 500, 215517. https://doi.org/10.1016/j.ccr.2023.215517. (共同通讯,IF = 20.6)
2、Organo-Se BTSAs-enabled performance: from Racemic and asymmetric synthesis to click-based application. Chem 2023, 9, 3335-3346. https://doi.org/10.1016/j.chempr.2023.07.022. (最后通讯,IF = 23.5)
3、Mask and Release Strategy-Enabled Diversity-Oriented Synthesis for DNA-Encoded Library. Adv. Sci. 2023, DOI: 10.1002/advs.202307049. https://doi.org/10.1002/advs.202307049. (最后通讯,IF = 15.1)
4、Evolution of chemistry and selection technology for DNA-encoded library. Acta Pharm. Sin. B 2023, DOI: 10.1016/j.apsb.2023.10.001. https://doi.org/10.1016/j.apsb.2023.10.001. (第一通讯,IF = 14.5)
5、Intermolecular Redox-Neutral Carboamination of C–C Multiple Bonds Initiated by Transition-Metal-Catalyzed C−H Activation. ACS Catal. 2022, 12, 14754–14772. https://doi.org/10.1021/acscatal.2c04964. (最后通讯,IF = 12.9)
6、Gem-Difluoromethylene Alkyne-Enabled Diverse C−H Functionalization and Application to the On-DNA Synthesis of Difluorinated Isocoumarins. Angew. Chem. Int. Ed. 2021, 60, 1959–1966. https://doi.org/10.1002/anie.202013052. (最后通讯,IF = 16.6)
7、Rhodium(III)-Catalyzed Enantio- and Diastereoselective C–H Cyclopropylation of N-Phenoxylsulfonamides: Combined Experimental and Computational Studies. Angew. Chem. Int. Ed. 2020, 59, 2890−2896. https://doi.org/10.1002/anie.201913794. (第一通讯,IF = 16.6)
8、Development of Novel Highly Potent Glucocorticoids for Steroid-Resistant Severe Asthma. PNAS 2019, 116, 6932-6937. https://doi.org/10.1073/pnas.181673411.(共同通讯,IF = 11.1)
9、Discovery of a Highly Potent Glucocorticoid for Asthma Treatment. Cell Discov. 2015, 1, 15035. https://doi.org/10.1038/celldisc.2015.35. (共同通讯,IF = 33.5)
10、Structures and Mechanism for the Design of Highly Potent Glucocorticoids. Cell Res. 2014, 24, 713-726. https://doi.org/10.1038/cr.2014.52. (共同通讯,IF = 44.1)
联系方式:
Email: yiwei@gzhmu.edu.cn